Page last updated: 2024-11-07

6-fluoromevalonolactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

6-Fluoromevalonolactone is a synthetic analog of mevalonolactone, a key intermediate in the biosynthesis of cholesterol and other isoprenoids. It acts as a potent inhibitor of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), the rate-limiting enzyme in cholesterol biosynthesis. Due to its ability to block cholesterol synthesis, 6-fluoromevalonolactone has been investigated as a potential therapeutic agent for hypercholesterolemia and other cardiovascular diseases. The compound has also been studied for its potential anti-inflammatory and anti-cancer properties. Synthesis of 6-fluoromevalonolactone typically involves fluorination of mevalonolactone or a suitable precursor. The compound is often used in research to study the regulation of cholesterol biosynthesis and the effects of HMG-CoA reductase inhibition.'
```

Cross-References

ID SourceID
PubMed CID119214
CHEMBL ID3185156
CHEBI ID125368
MeSH IDM0131500

Synonyms (20)

Synonym
4-(fluoromethyl)tetrahydro-4-hydroxy-2h-pyran-2-one
6-fluoromevalonate, >=90% (gc), viscous liquid
NCGC00165794-01
fluoromevalonate
CHEBI:125368
2822-77-7
4-(fluoromethyl)-4-hydroxyoxan-2-one
AKOS006285000
2h-pyran-2-one, 4-(fluoromethyl)tetrahydro-4-hydroxy-
6-fmva
6-fluoromevalonate
6-fluoromevalonolactone
zr 3516
BRD-A12426960-001-01-6
CHEMBL3185156
4-(fluoromethyl)-4-hydroxy-2-oxanone
Q27215723
J-017007
CS-0135985
HY-133957
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
delta-lactoneA lactone having a six-membered lactone ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.00000.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's6 (66.67)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]